A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMediLink Therapeutics (Suzhou) Co., Ltd.
About this trial
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Eligibility criteria
Qualifiers
Informed of the study before the start of the study and voluntarily sign their name and date in the ICF
Able and willing to comply with protocol visits and procedures
Age≥ 18 years
ECOG PS of 0 or 1
Disqualifiers
Prior treatment with an agent targeting CDH17
Prior discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities.
Have received an ADC consisting of a topoisomerase I inhibitor.
Concurrent enrollment in another clinical study, unless it is an observational clinical study.
Trial design
Treatments tested in this trial
- YL217
- YL217
- YL217
Treatment groups
220 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov